|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Basic and Translational Investigations |
Neuro-Oncology Research (W.K.P., N.C.H., W.P.H., J.P., A.C.S.), Neurosurgery Research Laboratory (W.K.P., M.C.P., A.C.S.), and Division of Neuropathology (S.W.C.), Barrow Neurological Institute of St. Joseph's Hospital and Medical Center, Phoenix, AZ 85013, USA
2 Address correspondence to Adrienne C. Scheck, Neuro-Oncology Research, Barrow Neurological Institute of St. Joseph's Hospital and Medical Center, 350 West Thomas Road, Phoenix, AZ 85013, USA (ascheck{at}chw.edu).
Abstract
We analyzed the frequency and regional distribution of cells with genetic abnormalities of chromosomes 1, 14, and 22 in meningiomas. This data was evaluated for correlation to the clinical outcome of the patients. Eight defined areas of each of 77 paraffin-embedded meningioma samples (59 grade I, 13 grade II, and 5 grade III) were analyzed by fluorescent in situ hybridization using bacterial artificial chromosome probes localized to chromosomes 1p36.32, 1q25.3, 14q13.3, 14q32.12, 22q11.2, and 22q12.1-3. Chromosome deletion was considered to be regionally heterogeneous if <7 regions showed cells with chromosome deletions. Deletion of 1p occurred in 35% of the grade I tumors. Distribution of cells with 1p deletion was regionally heterogeneous in 25% and homogeneous in 10% of grade I tumors. Distribution of cells with deletion of 1p was regionally heterogeneous in 23% and homogeneous in 69% of the grade II tumors. All grade III meningiomas had homogeneous distribution of cells with deletion of chromosome 1p. Distribution of cells with deletion of 14q was regionally heterogeneous in 27% and homogeneous in 2% of the grade I meningiomas, heterogeneous in 31% and homogeneous in 62% of the grade II tumors, and heterogeneous in 40% and homogeneous in 60% of the grade III meningiomas. Distribution of cells with deletion of 22q was regionally heterogeneous in 15% and homogeneous in 3% of the grade I tumors, heterogeneous in 15% and homogeneous in 31% of grade II tumors, and homogeneous in 20% of the grade III meningiomas. Distribution of cells with trisomy 22q was regionally heterogeneous in 10% of grade I tumors, heterogeneous in 23% of grade II, and homogeneous in 80% of grade III meningiomas. The proportion of patients with a deletion of 22q (either homogeneous or heterogeneous) who had recurrence was greater than the proportion of those without 22q deletion who had recurrence, and deletion of 22q was significantly associated with radiologically detected recurrence (P < 0.05). We conclude that the appearance of chromosomal aberrations in different areas of the tumor demonstrates the importance of regional heterogeneity in the biological behavior of meningiomas.
References
Adegbite, A.B., Khan, M.I., Paine, K.W., and Tan, L.K. (1983) The recurrence of intracranial meningiomas after surgical treatment. J. Neurosurg. 58, 51-56.[CrossRef][ISI][Medline]
Bello, M.J., de Campos, J.M., Kusak, M.E., Vaquero, J., Sarasa, J.L., Pestana, A., and Rey, J.A. (1994) Allelic loss at 1p is associated with tumor progression of meningiomas. Genes Chromosomes Cancer 9,296 -298.[ISI][Medline]
Bello, M.J., de Campos, J.M., Vaquero, J., Kusak, M.E., Sarasa, J.L., and Rey, J.A. (2000) High-resolution analysis of chromosome arm 1p alterations in meningioma. Cancer Genetics Cytogenet. 120,30 -36.
Bigner, D.D. (1981) Biology of gliomas: Potential clinical implications of glioma cellular heterogeneity. Neurosurgery 9,320 -326.[Medline]
Burger, P.C., and Kleihues, P. (1989) Cytologic composition of the untreated glioblastoma with implications for evaluation of needle biopsies. Cancer 63,2014 -2023.[CrossRef][ISI][Medline]
Cai, D.X., Banerjee, R., Scheithauer, B.W., Lohse, C.M., Kleinschmidt-DeMasters, B.K., and Perry, A. (2001) Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: Diagnostic and prognostic implications. J. Neuropathol. Exp. Neurol. 60,628 -636.[ISI][Medline]
Cairncross, J.G., Ueki, K., Zlatescu, M.C., Lisle, D.K.,
Findekstein, D.M., Hammond, R.R., Silver, J.S., Stark, P.C., Macdonald, D.R.,
Ino, Y., Ramsay, D.A., and Louis, D.N. (1998) Specific genetic
predictors of chemotherapeutic response and survival in patients with
anaplastic oligodendrogliomas. J. Natl. Cancer Inst.
90,1473
-1479.
Coons, S.W., and Johnson, P.C. (1992) Regional heterogeneity in the Ki67 labeling indexes of gliomas. J. Neuropathol. Exp. Neurol. 51,331 .
Coons, S.W., and Johnson, P.C. (1993a) Regional heterogeneity in the DNA content of human gliomas. Cancer 72,3052 -3060.[CrossRef][ISI][Medline]
Coons, S.W. and Johnson, P.C. (1993b) Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index. J. Neuropathol. Exp. Neurol. 52,609 -618.[ISI][Medline]
Coons, S.W., Johnson, P.C., and Shapiro, J.R. (1995)
Cytogenetic and flow cytometry DNA analysis of regional heterogeneity in a low
grade glioma. Cancer Res.
55,1569
-1577.
Deckert, M., Reifenberger, G., and Wechsler, W. (1989) Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67. J. Cancer Res. Clin. Oncol. 115,179 -188.[CrossRef][ISI][Medline]
DeMasters, B.K., Markham, N., Lillehei, K.O., and Shroyer, K.R. (1997) Differential telomerase expression in human primary intracranial tumors. Am. J. Clin. Pathol. 107,548 -554.[ISI][Medline]
Dunham, I., Dewar, K., Kim, U.-J., and Ross, M.T. (1999a) Bacterial Cloning Systems. In: Birren, B., Green, E.D., Klapholz, S., Myers, R.M., Riethman, H., and Roskams, J. (Eds.), Cloning Systems (Genome Analysis: A Laboratory Manual Series, Vol. 3). Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press, pp. 1-87.
Dunham, I., Shimizu, N., Roe, B.A., Chissoe, S., Hunt, A.R., Collins, J.E., Bruskiewich, R., Beare, D.M., Clamp, M., Smink, L.J., Ainscough, R., Almeida, J.P., Babbage, A., Bagguley, C., Bailey, J., Barlow, K., Bates, K.N., Beasley, O., Bird, C.P., Blakey, S., Bridgeman, A.M., Buck, D., Burgess, J., Burrill, W.D., O'Brien, K.P., et al. (1999b) The DNA sequence of chromosome 22. Nature 402,489 -495.[CrossRef][Medline]
Hsu, D.W., Efird, J.T., and Hedley-Whyte, E.T. (1997) Progesterone and estrogen receptors in meningiomas: Prognostic considerations. J. Neurosurg. 86,113 -120.[ISI][Medline]
Hsu, D.W., Efird, J.T., and Hedley-Whyte, E.T. (1998) MIB-1 (Ki-67) index and transforming growth factor-alpha (TGF alpha) immunoreactivity are significant prognostic predictors for meningiomas. Neuropathol. Appl. Neurobiol. 24,441 -452.[CrossRef][ISI][Medline]
Ino, Y., Zlatescu, M.C., Sasaki, H., Macdonald, D.R., Stemmer-Rachamimov, A.O., Jhung, S., Ramsay, D.A., von Deimling, A., Louis, D.N., and Cairncross, J.G. (2000) Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J. Neurosurg. 92,983 -990.[ISI][Medline]
Ishino, S., Hashimoto, N., Fushiki, S., Date, K., Mori, T., Fujimoto, M., Nakagawa, Y., Ueda, S., Abe, T., and Inazawa, J. (1998) Loss of material from chromosome arm 1p during malignant progression of meningioma revealed by fluorescent in situ hybridization. Cancer 83,360 -366.[CrossRef][Medline]
Jaaskelainen, J., Haltia, M., and Servo, A. (1986) Atypical and anaplastic meningiomas: Radiology, surgery, radiotherapy, and outcome. Surg. Neurol. 25,233 -242.[CrossRef][ISI][Medline]
Jung, H.W., Yoo, H., Paek, S.H., and Choi, K.S. (2000) Long-term outcome and growth rate of subtotally resected petroclival meningiomas: Experience with 38 cases. Neurosurgery 46,567 -574.[Medline]
Kallio, M., Sankila, R., Hakulinen, T., and Jaaskelainen, J. (1992) Factors affecting operative and excess long-term mortality in 935 patients with intracranial meningioma. Neurosurgery 31,2 -12.[Medline]
Kleinpeter, G., and Bock, F. (1990) Invasion of the cavernous sinus by medial sphenoid meningioma—"radical" surgery and recurrence. Acta Neurochir. 103, 87-91.[CrossRef]
Kujas, M. (1993) Meningioma. Curr. Opin. Neurol. 6,882 -887.[Medline]
Langford, L.A., Piatyszek, M.A., Xu, R., Schold, S.C., Jr., Wright, W.E., and Shay, J.W. (1997) Telomerase activity in ordinary meningiomas predicts poor outcome. Hum. Pathol. 28,416 -420.[CrossRef][ISI][Medline]
Leone, P.E., Bello, M.J., de Campos, J.M., Vaquero, J., Sarasa, J.L., Pestana, A., and Rey, J.A. (1999) NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene 18,2231 -2239.[CrossRef][ISI][Medline]
Lomas, J., Bello, M.J., Arjona, D., Gonzalez-Gomez, P., Alonso, M.E., de Campos, J.M., Vaquero, J., Ruiz-Barnes, P., Sarasa, J.L., Casartelli, C., and Rey, J.A. (2001) Analysis of p73 gene in meningiomas with deletion at 1p. Cancer Genetics Cytogenet. 129, 88-91.
Lopez-Gines, C., Cerda-Nicolas, M., Gil-Benso, R., Barcia-Salorio, J.L., and Llombart-Bosch, A. (2001) Loss of 1p in recurrent meningiomas. A comparative study in successive recurrences by cytogenetics and fluorescence in situ hybridization. Cancer Genetics Cytogenet. 125,119 -124.
Louis, D.N., Budka, H., and von Deimling, A. (1997) Meningiomas. In: Kleihues, P., and Cavenee, W.K. (Eds.), Pathology and Genetics of Tumours of the Nervous System. Lyon: International Agency for Research on Cancer, pp.133 -148.
Maillo, A., Diaz, P., Sayagues, J.M., Blanco, A., Tabernero, M.D., Ciudad, J., Lopez, A., Goncalves, J.M., and Orfao, A. (2001) Gains of chromosome 22 by fluorescence in situ hybridization in the context of an hyperdiploid karyotype are associated with aggressive clinical features in meningioma patients. Cancer 92,377 -385.[CrossRef][ISI][Medline]
Marks, S.M., Whitwell, H.L., and Lye, R.H. (1986) Recurrence of meningiomas after operation. Surg. Neurol. 25,436 -440.[Medline]
Muller, P., Henn, W., Niedermayer, I., Ketter, R., Feiden, W.,
Steudel, W.-I., Zang, K.D., and Steilen-Gimbel, H. (1999)
Deletion of chromosome 1p and loss of expression of alkaline phosphatase
indicate progression of meningiomas. Clin. Cancer Res.
5,3569
-3577.
Paulus, W., and Peiffer, J. (1989) Intratumoral histologic heterogeneity of gliomas. A quantitative study. Cancer 64,442 -447.[CrossRef][Medline]
Perry, A., Stafford, S.L., Scheithauer, B.W., Suman, V.J., and Lohse, C.M. (1997) Meningioma grading: An analysis of histologic parameters. Am. J. Surg. Pathol. 21,1455 -1465.[CrossRef][ISI][Medline]
Perry, A., Stafford, S.L., Scheithauer, B.W., Suman, V.J., and Lohse, C.M. (1998) The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer 82,2262 -2269.[CrossRef][ISI][Medline]
Perry, A., Scheithauer, B.W., Stafford, S.L., Lohse, C.M., and Wollan, P.C. (1999) "Malignancy" in meningiomas: A clinicopathologic study of 116 patients, with grading implications. Cancer 85,2046 -2056.[ISI][Medline]
Plate, K.H., Ruschoff, J., and Mennel, H.D. (1990) Nucleolar organizer regions in meningiomas. Correlation with histopathologic malignancy grading, DNA cytometry and clinical outcome. Anal. Quant. Cytol. Histol. 12,429 -438.[Medline]
Puchner, M.J., Fischer-Lampsatis, R.C., Herrmann, H.D., and Freckmann, N. (1998) Suprasellar meningiomas — neurological and visual outcome at long-term follow-up in a homogeneous series of patients treated microsurgically. Acta Neurochir. 140,1231 -1238.[CrossRef]
Sayagues, J.M., Tabernero, M.D., Maillo, A., Diaz, P., Rasillo, A., Bortoluci, A., Gomez-Moreta, J., Santos-Briz, A., Morales, F., and Orfao, A. (2002) Incidence of numerical chromosome aberrations in meningioma tumors as revealed by fluorescence in situ hybridization using 10 chromosome-specific probes. Cytometry 50,153 -159.[CrossRef][ISI][Medline]
Scheck, A.C., Beikman, M.K., Korn, M.C., and Shapiro, J.R. (1991) Regional analysis of genes potentially involved in resistance to BCNU in human malignant gliomas. Proc. Am. Assoc. Cancer Res. 32,358 (abstract 2125).
Scheck, A.C., Shapiro, J.R., Coons, S.W., Norman, S.A., and
Johnson, P.C. (1996) Biological and molecular analysis of a low
grade recurrence of a glioblastoma multiforme. Clin. Cancer
Res. 2,187
-199.
Schneider, B.F., Shashi, V., von Kap-Herr, C., and Golden, W.L. (1996) Loss of chromosomes 22 and 14 in the malignant progression of meningiomas. A comparative study of fluorescence in situ hybridization (FISH) and standard cytogenetic analysis. Cancer Genetics Cytogenet. 85,101 -104.
Shapiro, J.R., and Shapiro, W.R. (1985) The subpopulations and isolated cell types of freshly resected high grade human gliomas: Their influence on the tumor's evolution in vivo and behavior and therapy in vitro. Cancer Metastasis Rev. 4, 107-124.[CrossRef][ISI][Medline]
Sidransky, D., Mikkelsen, T., Schwechheimer, K., Rosenblum, M.L., Cavenee, W., and Vogelstein, B. (1992) Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355,846 -847.[CrossRef][Medline]
Simon, M., von Deimling, A., Larson, J.L., Wellenreuther, R.,
Kaskel, P., Waha, A., Warnick, R.E., Tew, J.M., Jr., and Menon, A.G.
(1995) Allelic losses on chromosomes 14, 10, and 1 in atypical
and malignant meningiomas: A genetic model of meningioma progression.
Cancer Res. 55,4696
-4701.
Simon, M., Park, T.W., Leuenroth, S., Hans, V.H., Loning, T., and Schramm, J. (2000) Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression. J. Neurosurg. 92,832 -840.[ISI][Medline]
Simon, M., Park, T.W., Koster, G., Mahlberg, R., Hackenbroch, M., Bostrom, J., Loning, T., and Schramm, J. (2001) Alterations of INK4a(p16–p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression. J. Neurooncol. 55,149 -158.[CrossRef][Medline]
Simpson, D. (1957) The recurrence of intracranial meningiomas after surgical treatment. J. Neurol. Neurosurg. Psychiatr. 20,22 -39.
Strommer, K., Hamou, M.F., Diggelmann, H., and de Tribolet, N. (1990) Cellular and tumoural heterogeneity of EGFR gene amplification in human malignant gliomas. Acta Neurochir. 107,82 -87.
Ueki, K., Wen-Bin, C., Narita,Y., Asai, A., and Kirino, T.
(1999) Tight association of loss of merlin expression with loss
of heterozygosity at chromosome 22q in sporadic meningiomas. Cancer
Res. 59,5995
-5998.
Yakut, T., Bekar, A., Doygun, M., Acar, H., Egeli, U., and Ogul, E. (2002) Evaluation of relationship between chromosome 22 and p53 gene alterations and the subtype of meningiomas by the interphase-FISH technique. Teratogenesis Carcinog. Mutagen. 22,217 -225.
Zattara-Cannoni, H., Gambarelli, D., Dufour, H., Figarella, D., Vollot, F., Grisoli, F., and Vagner-Capodano, A.M. (1998) Contribution of cytogenetics and FISH in the diagnosis of meningiomas. A study of 189 tumors. Ann. Genet. 41,164 -175.[ISI][Medline]
This article has been cited by other articles:
|
|
 |
|
  A. B. Espinosa, M. D. Tabernero, A. Maillo, J. M. Sayagues, J. Ciudad, M. Merino, M. C. Alguero, A. M. Lubombo, P. Sousa, A. Santos-Briz, et al. The Cytogenetic Relationship between Primary and Recurrent Meningiomas Points to the Need for New Treatment Strategies in Cases at High Risk of Relapse Clin. Cancer Res., February 1, 2006; 12(3): 772 - 780. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
